Published in Urology on August 01, 1996
Targeted delivery of cisplatin to prostate cancer cells by aptamer functionalized Pt(IV) prodrug-PLGA-PEG nanoparticles. Proc Natl Acad Sci U S A (2008) 3.62
The diagnostic value of PET/CT imaging with the (68)Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol Imaging (2014) 3.40
Engineering of self-assembled nanoparticle platform for precisely controlled combination drug therapy. Proc Natl Acad Sci U S A (2010) 2.21
Targeted delivery of a cisplatin prodrug for safer and more effective prostate cancer therapy in vivo. Proc Natl Acad Sci U S A (2011) 2.16
Preclinical evaluation of novel glutamate-urea-lysine analogues that target prostate-specific membrane antigen as molecular imaging pharmaceuticals for prostate cancer. Cancer Res (2009) 2.03
Biodistribution, tumor detection, and radiation dosimetry of 18F-DCFBC, a low-molecular-weight inhibitor of prostate-specific membrane antigen, in patients with metastatic prostate cancer. J Nucl Med (2012) 2.00
Initial Evaluation of [(18)F]DCFPyL for Prostate-Specific Membrane Antigen (PSMA)-Targeted PET Imaging of Prostate Cancer. Mol Imaging Biol (2015) 1.90
Noninvasive measurement of androgen receptor signaling with a positron-emitting radiopharmaceutical that targets prostate-specific membrane antigen. Proc Natl Acad Sci U S A (2011) 1.87
PSMA PET/CT with Glu-urea-Lys-(Ahx)-[(68)Ga(HBED-CC)] versus 3D CT volumetric lymph node assessment in recurrent prostate cancer. Eur J Nucl Med Mol Imaging (2015) 1.86
Functional characterization of circulating tumor cells with a prostate-cancer-specific microfluidic device. PLoS One (2012) 1.86
2-(3-{1-Carboxy-5-[(6-[18F]fluoro-pyridine-3-carbonyl)-amino]-pentyl}-ureido)-pentanedioic acid, [18F]DCFPyL, a PSMA-based PET imaging agent for prostate cancer. Clin Cancer Res (2011) 1.69
Myc confers androgen-independent prostate cancer cell growth. J Clin Invest (2003) 1.65
A novel cytoplasmic tail MXXXL motif mediates the internalization of prostate-specific membrane antigen. Mol Biol Cell (2003) 1.60
Anti-prostate-specific membrane antigen-based radioimmunotherapy for prostate cancer. Cancer (2010) 1.57
Novel tracers and their development for the imaging of metastatic prostate cancer. J Nucl Med (2008) 1.56
PET imaging in prostate cancer: focus on prostate-specific membrane antigen. Curr Top Med Chem (2013) 1.42
Advances in immuno-positron emission tomography: antibodies for molecular imaging in oncology. J Clin Oncol (2012) 1.39
Quantitative (18)F-fluorocholine positron emission tomography for prostate cancer: correlation between kinetic parameters and Gleason scoring. EJNMMI Res (2017) 1.37
Overview of prostate-specific membrane antigen. Rev Urol (2004) 1.34
Tissue prostate-specific antigen facilitates refractory prostate tumor progression via enhancing ARA70-regulated androgen receptor transactivation. Cancer Res (2008) 1.22
Prostate-specific membrane antigen-based imaging. Urol Oncol (2012) 1.22
¹⁸F-DCFBC PET/CT for PSMA-Based Detection and Characterization of Primary Prostate Cancer. J Nucl Med (2015) 1.21
Characterization of a targeted nanoparticle functionalized with a urea-based inhibitor of prostate-specific membrane antigen (PSMA). Cancer Biol Ther (2008) 1.18
Detection of circulating tumor cells in prostate cancer patients: methodological pitfalls and clinical relevance. Mol Med (2008) 1.16
GCPII imaging and cancer. Curr Med Chem (2012) 1.12
Developing imaging strategies for castration resistant prostate cancer. Acta Oncol (2011) 1.10
Targeting the internal epitope of prostate-specific membrane antigen with 89Zr-7E11 immuno-PET. J Nucl Med (2011) 1.07
Induction of autoantibodies to syngeneic prostate-specific membrane antigen by xenogeneic vaccination. Int J Cancer (2005) 1.07
Moderate expression of prostate-specific membrane antigen, a tissue differentiation antigen and folate hydrolase, facilitates prostate carcinogenesis. Cancer Res (2008) 1.07
Prostate-specific membrane antigen-based therapeutics. Adv Urol (2011) 1.06
Targeted inhibition of prostate cancer metastases with an RNA aptamer to prostate-specific membrane antigen. Mol Ther (2014) 1.04
The prostate-specific membrane antigen: lessons and current clinical implications from 20 years of research. Urol Oncol (2013) 1.04
Prodrugs for improving tumor targetability and efficiency. Adv Drug Deliv Rev (2011) 1.00
Molecular imaging of prostate cancer. Curr Opin Urol (2012) 0.98
PET imaging of prostate-specific membrane antigen in prostate cancer: current state of the art and future challenges. Prostate Cancer Prostatic Dis (2016) 0.95
Biorecognition and subcellular trafficking of HPMA copolymer-anti-PSMA antibody conjugates by prostate cancer cells. Mol Pharm (2009) 0.95
Towards Personalized Treatment of Prostate Cancer: PSMA I&T, a Promising Prostate-Specific Membrane Antigen-Targeted Theranostic Agent. Theranostics (2016) 0.94
PSMA Ligands for Radionuclide Imaging and Therapy of Prostate Cancer: Clinical Status. Theranostics (2015) 0.94
⁶⁴Cu-labeled inhibitors of prostate-specific membrane antigen for PET imaging of prostate cancer. J Med Chem (2014) 0.94
Prostate cancer relevant antigens and enzymes for targeted drug delivery. J Control Release (2014) 0.93
Prostate-specific membrane antigen protein expression in tumor tissue and risk of lethal prostate cancer. Cancer Epidemiol Biomarkers Prev (2013) 0.93
Microtubule inhibitor-based antibody-drug conjugates for cancer therapy. Onco Targets Ther (2014) 0.93
Comparison of Prostate-Specific Membrane Antigen-Based 18F-DCFBC PET/CT to Conventional Imaging Modalities for Detection of Hormone-Naïve and Castration-Resistant Metastatic Prostate Cancer. J Nucl Med (2015) 0.91
Immunocapture of prostate cancer cells by use of anti-PSMA antibodies in microdevices. Biomed Microdevices (2012) 0.91
Co-expression and impact of prostate specific membrane antigen and prostate specific antigen in prostatic pathologies. J Exp Clin Cancer Res (2010) 0.90
Molecularly targeted agents as radiosensitizers in cancer therapy--focus on prostate cancer. Int J Mol Sci (2013) 0.89
Measuring oncogenic signaling pathways in cancer with PET: an emerging paradigm from studies in castration-resistant prostate cancer. Cancer Discov (2012) 0.89
Prostate-specific membrane antigen associates with anaphase-promoting complex and induces chromosomal instability. Mol Cancer Ther (2008) 0.88
Role of TMPRSS2-ERG gene fusion in negative regulation of PSMA expression. PLoS One (2011) 0.88
Biodistributions of 177Lu- and 111In-labeled 7E11 antibodies to prostate-specific membrane antigen in xenograft model of prostate cancer and potential use of 111In-7E11 as a pre-therapeutic agent for 177Lu-7E11 radioimmunotherapy. Mol Imaging Biol (2008) 0.88
PSMA-Based [(18)F]DCFPyL PET/CT Is Superior to Conventional Imaging for Lesion Detection in Patients with Metastatic Prostate Cancer. Mol Imaging Biol (2016) 0.87
Androgen-independent molecular imaging vectors to detect castration-resistant and metastatic prostate cancer. Cancer Res (2011) 0.87
The evolution of imaging in cancer: current state and future challenges. Semin Oncol (2011) 0.87
Opposing roles of folate in prostate cancer. Urology (2013) 0.86
Vaccines as monotherapy and in combination therapy for prostate cancer. Clin Transl Sci (2010) 0.85
Molecular staging of prostate cancer in the year 2007. World J Urol (2007) 0.85
Alterations in androgen deprivation enhanced prostate-specific membrane antigen (PSMA) expression in prostate cancer cells as a target for diagnostics and therapy. EJNMMI Res (2015) 0.84
Molecular targeting of angiogenesis for imaging and therapy. Eur J Nucl Med Mol Imaging (2004) 0.82
Molecular imaging of prostate cancer: translating molecular biology approaches into the clinical realm. Eur Radiol (2015) 0.82
The emergence of radioimmunoscintigraphy for prostate cancer. Rev Urol (2006) 0.80
Uptake of (18)F-DCFPyL in Paget's Disease of Bone, an Important Potential Pitfall in Clinical Interpretation of PSMA PET Studies. Tomography (2015) 0.80
Improved performance of SPECT-CT In-111 capromab pendetide by correlation with diffusion-weighted magnetic resonance imaging for identifying metastatic pelvic lymphadenopathy in prostate cancer. World J Urol (2013) 0.79
Discriminatory Role of Detergent-Resistant Membranes in the Dimerization and Endocytosis of Prostate-Specific Membrane Antigen. PLoS One (2013) 0.79
Prostate cancer radiotherapy: potential applications of metal nanoparticles for imaging and therapy. Br J Radiol (2015) 0.79
Bone marrow recovery and subsequent chemotherapy following radiolabeled anti-prostate-specific membrane antigen monoclonal antibody j591 in men with metastatic castration-resistant prostate cancer. Front Oncol (2013) 0.79
Prostate-cancer-targeted N-(2-hydroxypropyl)methacrylamide copolymer/docetaxel conjugates. Macromol Biosci (2012) 0.79
Radioiodine therapy for castration-resistant prostate cancer following prostate-specific membrane antigen promoter-mediated transfer of the human sodium iodide symporter. Asian J Androl (2013) 0.79
Comparison of (68)Ga-HBED-CC PSMA-PET/CT and multiparametric MRI for gross tumour volume detection in patients with primary prostate cancer based on slice by slice comparison with histopathology. Theranostics (2017) 0.78
Development of inhibitor-directed enzyme prodrug therapy (IDEPT) for prostate cancer. Bioconjug Chem (2014) 0.78
The clinical role of multimodality imaging in the detection of prostate cancer recurrence after radical prostatectomy and radiation therapy: past, present, and future. Ecancermedicalscience (2015) 0.78
Co-administration of a DNA vaccine encoding the prostate specific membrane antigen and CpG oligodeoxynucleotides suppresses tumor growth. J Transl Med (2004) 0.78
Preclinical evaluation of BAY 1075553, a novel (18)F-labelled inhibitor of prostate-specific membrane antigen for PET imaging of prostate cancer. Eur J Nucl Med Mol Imaging (2013) 0.78
(R)-NODAGA-PSMA: A Versatile Precursor for Radiometal Labeling and Nuclear Imaging of PSMA-Positive Tumors. PLoS One (2015) 0.78
Specific Delivery of MiRNA for High Efficient Inhibition of Prostate Cancer by RNA Nanotechnology. Mol Ther (2016) 0.78
Comparison of PSMA-HBED and PSMA-I&T as diagnostic agents in prostate carcinoma. Eur J Nucl Med Mol Imaging (2017) 0.77
PSMA targeted docetaxel-loaded superparamagnetic iron oxide nanoparticles for prostate cancer. Colloids Surf B Biointerfaces (2016) 0.77
Prostate specific membrane antigen mRNA in blood as a potential predictor of biochemical recurrence after radical prostatectomy. J Korean Med Sci (2010) 0.77
A multivalent approach of imaging probe design to overcome an endogenous anion binding competition for noninvasive assessment of prostate specific membrane antigen. Mol Pharm (2013) 0.77
DNA vaccination for prostate cancer, from preclinical to clinical trials - where we stand? Genet Vaccines Ther (2012) 0.77
Diagnostic performance of (68)Ga-PSMA-11 (HBED-CC) PET/CT in patients with recurrent prostate cancer: evaluation in 1007 patients. Eur J Nucl Med Mol Imaging (2017) 0.77
Prostate-specific membrane antigen-targeted liposomes specifically deliver the Zn(2+) chelator TPEN inducing oxidative stress in prostate cancer cells. Nanomedicine (Lond) (2016) 0.76
Targeted Radionuclide Therapy: An Evolution Toward Precision Cancer Treatment. AJR Am J Roentgenol (2017) 0.75
Bone marrow metastasis of prostatic adenocarcinoma with post-treatment foamy-like changes: A diagnostic pitfall. Can Urol Assoc J (2014) 0.75
Molecular imaging of urogenital diseases. Semin Nucl Med (2014) 0.75
Repeated PSMA-targeting radioligand therapy of metastatic prostate cancer with (131)I-MIP-1095. Eur J Nucl Med Mol Imaging (2017) 0.75
68Ga-PSMA-11 PET Imaging of Response to Androgen Receptor Inhibition: First Human Experience. J Nucl Med (2016) 0.75
68Ga-PSMA-11 PET/CT for prostate cancer staging and risk stratification in Chinese patients. Oncotarget (2017) 0.75
Preclinical and first clinical experience with the gastrin-releasing peptide receptor-antagonist [(68)Ga]SB3 and PET/CT. Eur J Nucl Med Mol Imaging (2015) 0.75
Preliminary evaluation of prostate-targeted radiotherapy using (131) I-MIP-1095 in combination with radiosensitising chemotherapeutic drugs. J Pharm Pharmacol (2016) 0.75
68Ga-PSMA PET/CT imaging in recurrent prostate cancer: Where are we now? Cent European J Urol (2017) 0.75
Characterization of a novel metastatic prostate cancer cell line of LNCaP origin. Prostate (2015) 0.75
In vitro and in vivo effects of a recombinant anti-PSMA immunotoxin in combination with docetaxel against prostate cancer. Oncotarget (2016) 0.75
Full preclinical validation of the 123I-labeled anti-PSMA antibody fragment ScFvD2B for prostate cancer imaging. Oncotarget (2016) 0.75
Prostate immunotherapy: should all guns be aimed at the prostate-specific antigen? Immunotherapy (2013) 0.75
Clinical performance of (68)Ga-PSMA-11 PET/MRI for the detection of recurrent prostate cancer following radical prostatectomy. Eur J Nucl Med Mol Imaging (2017) 0.75
Clinical Utility of Gallium-68 PSMA PET/CT Scan for Prostate Cancer. Indian J Nucl Med (2017) 0.75
PSMA-Targeted Theranostic Nanocarrier for Prostate Cancer. Theranostics (2017) 0.75
Results of radical prostatectomy in men with clinically localized prostate cancer. JAMA (1996) 2.74
On-site, rapid HIV testing with same-day results and counseling. AIDS (1997) 2.44
Cytotoxic chemotherapy for advanced hormone-resistant prostate cancer. Cancer (1993) 2.31
Development of a novel proteomic approach for the detection of transitional cell carcinoma of the bladder in urine. Am J Pathol (2001) 2.15
Fifteen-year minimum follow-up of a prostate brachytherapy series: comparing the past with the present. Urology (2000) 2.15
Use of short-course class 1 topical glucocorticoid under occlusion for the rapid control of erythrodermic psoriasis. Arch Dermatol (1994) 2.03
Chemotherapy for advanced renal-cell carcinoma: 1983-1993. Semin Oncol (1995) 1.83
Altered expression of the retinoblastoma gene product: prognostic indicator in bladder cancer. J Natl Cancer Inst (1992) 1.81
Randomised controlled trial of cognitive-behavioural therapy in early schizophrenia: acute-phase outcomes. Br J Psychiatry Suppl (2002) 1.75
Proteinchip(R) surface enhanced laser desorption/ionization (SELDI) mass spectrometry: a novel protein biochip technology for detection of prostate cancer biomarkers in complex protein mixtures. Prostate Cancer Prostatic Dis (1999) 1.73
Results of a multicenter trial using the BTA test to monitor for and diagnose recurrent bladder cancer. J Urol (1995) 1.71
Performance of a rapid, on-site human immunodeficiency virus antibody assay in a public health setting. J Clin Microbiol (1995) 1.58
Identification of potential CSF biomarkers in ALS. Neurology (2006) 1.50
Serum prostate specific antigen is a strong predictor of future prostate growth in men with benign prostatic hyperplasia. PROSCAR long-term efficacy and safety study. J Urol (2000) 1.47
Expression of prostate-specific membrane antigen in normal, benign, and malignant prostate tissues. Urol Oncol (2011) 1.45
Prostate-specific antigen for pretreatment prediction and posttreatment evaluation of outcome after definitive irradiation for prostate cancer. Int J Radiat Oncol Biol Phys (1995) 1.45
DNA microsatellite analysis of Dolly. Nature (1998) 1.42
Pulmonary metastases from prostate cancer. Cancer (1995) 1.42
Estramustine and vinblastine: use of prostate specific antigen as a clinical trial end point for hormone refractory prostatic cancer. J Urol (1992) 1.34
QTL for body weight, morphometric traits and stress response in European sea bass Dicentrarchus labrax. Anim Genet (2009) 1.27
Cytotoxic chemotherapy for advanced renal cell carcinoma. Urol Clin North Am (1993) 1.27
Malignant pericardial effusion as initial solitary site of metastasis from transitional cell carcinoma of the bladder. Urology (1995) 1.26
Goserelin versus orchiectomy in the treatment of advanced prostate cancer: final results of a randomized trial. Zoladex Prostate Study Group. Urology (1995) 1.23
Spontaneous regression of metastatic renal cell carcinoma. Urology (1982) 1.22
Quality of life after treatment for localized prostate cancer: differences based on treatment modality. J Urol (2001) 1.22
Tolerance of high-dose (3,000 mg/day) coenzyme Q10 in ALS. Neurology (2005) 1.21
Postoperative brainstem and cerebellar infarcts. Neurology (1993) 1.14
Results of radical prostatectomy in men with locally advanced prostate cancer: multi-institutional pooled analysis. Eur Urol (1997) 1.11
A linkage map of the porcine genome from a large-scale White Duroc x Erhualian resource population and evaluation of factors affecting recombination rates. Anim Genet (2009) 1.10
Quantitation of serum prostate-specific membrane antigen by a novel protein biochip immunoassay discriminates benign from malignant prostate disease. Cancer Res (2001) 1.10
Four cases of metastases to the penis and a review of the literature. J Urol (1984) 1.10
The adrenal gland and renal cell carcinoma: is ipsilateral adrenalectomy a necessary component of radical nephrectomy? J Urol (1986) 1.09
Combined androgen blockade with nonsteroidal antiandrogens for advanced prostate cancer: a systematic review. Urology (2001) 1.06
Changing pattern of expression of the epidermal growth factor receptor and transforming growth factor alpha in the progression of prostatic neoplasms. Clin Cancer Res (1995) 1.06
Characteristics of spinal cord compression in adenocarcinoma of prostate. Urology (1986) 1.01
A review of urologic cancer patients with multiple primary malignancies. World J Urol (2001) 1.01
Borrelia burgdorferi in eastern Virginia: comparison between a coastal and inland locality. Am J Trop Med Hyg (1995) 1.01
Randomized intergroup comparison of bacillus calmette-guerin immunotherapy and mitomycin C chemotherapy prophylaxis in superficial transitional cell carcinoma of the bladder a southwest oncology group study. Urol Oncol (2011) 1.00
Improved detection of recurrent bladder cancer using the Bard BTA stat Test. Urology (1997) 1.00
Comparative quality-of-life analysis after radical prostatectomy or external beam radiation for localized prostate cancer. Urology (1999) 0.98
Re: Intravesical bacillus Calmette-Guerin therapy and associated granulomatous renal masses. J Urol (1987) 0.97
Conservative surgical therapy for penile and urethral carcinoma. Urology (1999) 0.95
Zoladex versus orchiectomy in treatment of advanced prostate cancer: a randomized trial. Zoladex Prostate Study Group. Urology (1991) 0.95
The use of microsurgical denervation of the spermatic cord for orchialgia. Trans Am Assoc Genitourin Surg (1978) 0.94
Effect of local tumor control on distant metastasis and survival in prostatic adenocarcinoma. Urology (1987) 0.94
Immediate adjuvant intravesical chemotherapy after transurethral resection of bladder tumor. Curr Opin Urol (1998) 0.94
Docetaxel (Taxotere) and estramustine versus mitoxantrone and prednisone for hormone-refractory prostate cancer: scientific basis and design of Southwest Oncology Group Study 9916. Semin Oncol (1999) 0.92
Seroprevalence of and risk factors for Toxoplasma gondii in the US swine herd using sera collected during the National Animal Health Monitoring Survey (Swine 2006). Zoonoses Public Health (2009) 0.92
Evidence for nerve growth factor-mediated paracrine effects in human epidermis. J Cell Biol (1991) 0.92
Renal metastases from carcinoma of the lung. Br J Urol (1986) 0.92
Comparison of goserelin and leuprolide in combined androgen blockade therapy. Urology (1998) 0.91
Determination of the "reflex range" and appropriate cutpoints for percent free prostate-specific antigen in 413 men referred for prostatic evaluation using the AxSYM system. Urology (1997) 0.91
Effects of suramin-related and other clinically therapeutic polyanions on protein kinase C activity. Clin Cancer Res (1995) 0.91
Prostatic involvement by transitional cell carcinoma: pathogenesis, patterns and prognosis. J Urol (1977) 0.91
Quantitative trait loci for resistance to fish pasteurellosis in gilthead sea bream (Sparus aurata). Anim Genet (2010) 0.90
Histochemical studies of the myocardium and conduction system in acquired iron-storage disease. Circulation (1967) 0.90
Calcium signaling in prostate cancer cells: evidence for multiple receptors and enhanced sensitivity to bombesin/GRP. Prostate (1997) 0.89
Additional bacillus Calmette-Guérin therapy for recurrent transitional cell carcinoma after an initial complete response. Urology (1997) 0.89
True and false positive peaks in genomewide scans: The long and the short of it. Genet Epidemiol (2001) 0.89
Light scatter and total protein signal distribution of platelets by flow cytometry as parameters of size. J Lab Clin Med (1988) 0.88
Management of patients with Bacilli Calmette-Guérin-refractory carcinoma in situ of the urinary bladder: cost implications of a clinical trial for valrubicin. Clin Ther (2000) 0.88
Giant hydronephrosis of a duplex system associated with ureteral ectopia. J Urol (1989) 0.87
Estrogen receptor activity in a case of Hodgkin's disease. Ann Intern Med (1981) 0.87
Bacillus Calmette-Guerin for superficial transitional cell carcinoma of the bladder. J Urol (1986) 0.87
Prevention of N-methyl-N-nitrosourea-induced mammary carcinogenesis in rats by 1alpha-hydroxyvitamin D(5). J Natl Cancer Inst (2000) 0.86
Prostate-specific membrane antigen levels in sera from healthy men and patients with benign prostate hyperplasia or prostate cancer. Clin Cancer Res (1999) 0.86
BoLA-DR peptide binding pockets are fundamental for foot-and-mouth disease virus vaccine design in cattle. Vaccine (2009) 0.86
Cure of undifferentiated small cell carcinoma of the urinary bladder with M-VAC chemotherapy. Urol Oncol (2001) 0.85
A dose-response study of the effect of flutamide on benign prostatic hyperplasia: results of a multicenter study. Urology (1996) 0.84
Colitis and docetaxel-based chemotherapy. Lancet (2000) 0.84
Does prolonged combined androgen blockade have survival benefits over short-term combined androgen blockade therapy? Urology (2000) 0.84
Partial cystectomy during radical surgery for nonurological malignancy. J Urol (2001) 0.84
Serum levels of endothelial and neural cell adhesion molecules in prostate cancer. Prostate (1997) 0.84
Genetic diversity in European pigs utilizing amplified fragment length polymorphism markers. Anim Genet (2006) 0.83
Cytogenetic evaluation of 20 cultured primary prostatic tumors. Cancer Genet Cytogenet (1991) 0.83
The effect of TURP on prognosis in prostatic carcinoma. Int J Radiat Oncol Biol Phys (1987) 0.83
Prognosis in patients with local recurrence after definitive irradiation for prostatic carcinoma. Cancer (1989) 0.83
Intravesical chemotherapy and immunotherapy for superficial tumors Basic mechanism of action and future direction. Urol Oncol (2011) 0.83
Transitional cell carcinoma of the urethra in men having cystectomy for bladder cancer. J Urol (1976) 0.83
Carcinoma of the prostate: race as a prognostic indicator in definitive radiation therapy. Radiology (1995) 0.83
Outcomes after intravesical bacillus Calmette-Guerin are not affected by substaging of high grade T1 transitional cell carcinoma. J Urol (2000) 0.83
Analysis of prostatic tumor cultures using fluorescence in-situ hybridization (FISH). Cancer Genet Cytogenet (1992) 0.83
PSA for outcome prediction and posttreatment evaluation following radiation for prostate cancer: do we know how to use it? Semin Radiat Oncol (1998) 0.82
IgE antibody production in guinea pigs treated with cyclophosphamide. J Immunol (1981) 0.82
Implicit and explicit memory in pregnant women: an analysis of data-driven and conceptually driven processes. Q J Exp Psychol A (2000) 0.82
Current methods of assessing and treating carcinoma in situ of the bladder with or without involvement of the prostatic urethra. Int J Urol (1995) 0.82
Immunohistochemical localization of prostate carcinoma-associated antigens. Cancer Res (1983) 0.82
Solitary lesions on bone scan in genitourinary malignancy. J Urol (1984) 0.82
Major rectal complications following interstitial implantation of 125iodine for carcinoma of the prostate. J Urol (1985) 0.82
Massive intrascrotal fibrolipoma. J Urol (1983) 0.81
Pelvic complications after interstitial and external beam irradiation of urologic and gynecologic malignancy. World J Surg (1986) 0.81
Endocrine effects, efficacy and tolerability of a 10.8-mg depot formulation of goserelin acetate administered every 13 weeks to patients with advanced prostate cancer. BJU Int (1999) 0.81
Squamous cell carcinoma at the prostatectomy site: squamous differentiation of recurrent prostate carcinoma. Urology (1999) 0.81
Squamous cell carcinoma of bladder after successful intravesical therapy with Bacillus Calmette-Guérin. Urology (1989) 0.81
Age-adjusted CD4+ lymphocyte parameters in healthy children at risk for infection with the human immunodeficiency virus. The Military Pediatric HIV Consortium. Clin Infect Dis (1993) 0.81
I-125 interstitial implantation for prostate cancer. What have we learned 10 years later? Cancer (1989) 0.81